Tags

Type your tag names separated by a space and hit enter

[Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant].
J Fr Ophtalmol. 2016 Jan; 39(1):5-11.JF

Abstract

PURPOSE

To evaluate the efficacy of dexamethasone 0.7 mg intravitreal implant in patients with postoperative cystoid macular edema.

MATERIALS AND METHODS

Fourteen patients' charts with postoperative cystoid macular edema were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT).

RESULTS

Patients' mean age was 72.1 years old. Five patients were diabetic. All patients had previously been treated with non-steroidal anti-inflammatory drops. Four patients had received a previous treatment with intravitreal ranibizumab. The mean follow-up period was 8.7 months. Mean BCVA before intravitreal dexamethasone was 0.72 logMAR. After injection, it improved to 0.50 at month 1, was 0.47 at month 3, and 0.60 logMAR at month 12. The pre-injection mean CRT was 598 μm. It improved to 286 μm at month 1, 338 μm at month 3, and was 441 μm at month 12. Eight patients received 2 intravitreal injections of dexamethasone. Five patients presented with elevated intraocular pressure during follow-up, which was treated with drops.

CONCLUSIONS

Intravitreal dexamethasone injection improved visual acuity and macular thickness at month 1 and month 3 in patients with postoperative cystoid macular edema. A second injection was necessary after a mean period of 5 months.

Authors+Show Affiliations

Hôpital Pasteur 2, 30, avenue de la Voie-Romaine, 06000 Nice, France.Cabinet Nice-Retina, 5, rue Eugène-Emmanuel, 06000 Nice, France.Hôpital Pasteur 2, 30, avenue de la Voie-Romaine, 06000 Nice, France.Hôpital Pasteur 2, 30, avenue de la Voie-Romaine, 06000 Nice, France. Electronic address: baillif.s@chu-nice.fr.

Pub Type(s)

Journal Article

Language

fre

PubMed ID

26520410

Citation

Landré, C, et al. "[Treatment of Postoperative Cystoid Macular Edema (Irvine-Gass Syndrome) With Dexamethasone 0.7 Mg Intravitreal Implant]." Journal Francais D'ophtalmologie, vol. 39, no. 1, 2016, pp. 5-11.
Landré C, Zourdani A, Gastaud P, et al. [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant]. J Fr Ophtalmol. 2016;39(1):5-11.
Landré, C., Zourdani, A., Gastaud, P., & Baillif, S. (2016). [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant]. Journal Francais D'ophtalmologie, 39(1), 5-11. https://doi.org/10.1016/j.jfo.2015.03.011
Landré C, et al. [Treatment of Postoperative Cystoid Macular Edema (Irvine-Gass Syndrome) With Dexamethasone 0.7 Mg Intravitreal Implant]. J Fr Ophtalmol. 2016;39(1):5-11. PubMed PMID: 26520410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant]. AU - Landré,C, AU - Zourdani,A, AU - Gastaud,P, AU - Baillif,S, Y1 - 2015/10/29/ PY - 2014/12/08/received PY - 2015/03/25/revised PY - 2015/03/26/accepted PY - 2015/11/2/entrez PY - 2015/11/2/pubmed PY - 2016/11/2/medline KW - Cataract surgery KW - Chirurgie de la cataracte KW - Implant intravitréen de déxamethasone KW - Intravitreal dexamethasone implant KW - Irvine-Gass syndrome KW - Postoperative cystoid macular edema KW - Syndrome d’Irvine-Gass KW - Œdème maculaire postopératoire SP - 5 EP - 11 JF - Journal francais d'ophtalmologie JO - J Fr Ophtalmol VL - 39 IS - 1 N2 - PURPOSE: To evaluate the efficacy of dexamethasone 0.7 mg intravitreal implant in patients with postoperative cystoid macular edema. MATERIALS AND METHODS: Fourteen patients' charts with postoperative cystoid macular edema were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT). RESULTS: Patients' mean age was 72.1 years old. Five patients were diabetic. All patients had previously been treated with non-steroidal anti-inflammatory drops. Four patients had received a previous treatment with intravitreal ranibizumab. The mean follow-up period was 8.7 months. Mean BCVA before intravitreal dexamethasone was 0.72 logMAR. After injection, it improved to 0.50 at month 1, was 0.47 at month 3, and 0.60 logMAR at month 12. The pre-injection mean CRT was 598 μm. It improved to 286 μm at month 1, 338 μm at month 3, and was 441 μm at month 12. Eight patients received 2 intravitreal injections of dexamethasone. Five patients presented with elevated intraocular pressure during follow-up, which was treated with drops. CONCLUSIONS: Intravitreal dexamethasone injection improved visual acuity and macular thickness at month 1 and month 3 in patients with postoperative cystoid macular edema. A second injection was necessary after a mean period of 5 months. SN - 1773-0597 UR - https://www.unboundmedicine.com/medline/citation/26520410/[Treatment_of_postoperative_cystoid_macular_edema__Irvine_Gass_syndrome__with_dexamethasone_0_7_mg_intravitreal_implant]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0181-5512(15)00301-0 DB - PRIME DP - Unbound Medicine ER -